Auto Amazon Links: No products found.
New guidance for the NHS recommends that women diagnosed with polyendocrine metabolic ovarian syndrome (PMOS) undergo yearly health screenings to identify the numerous complications linked to this multifaceted condition. Affecting approximately one in eight women, PMOS — previously referred to as polycystic ovary syndrome — received its updated name in May to more accurately convey the wide-ranging effects it can have on the body.
The draft guidelines released by the National Institute for Health and Care Excellence (NICE) emphasize the importance of quicker diagnosis and improved ongoing monitoring. PMOS is a leading cause of infertility among women, with symptoms that commonly include irregular menstrual cycles, increased hair growth, and weight gain. Despite its prevalence, with an estimated three to four million women in the UK affected, the condition remains significantly underdiagnosed and inconsistently treated according to NICE.
NICE suggests that annual checkups for women with PMOS should extend beyond evaluating immediate symptoms to also consider long-term health risks such as diabetes and cardiovascular disease. The guidance highlights that lifestyle modifications alongside medical treatment could reduce the likelihood of developing serious complications. Although there is no cure for PMOS, the NHS offers various treatments designed to alleviate symptoms, including hormone therapies and fertility medications. Notably, the new advice advises against using laser and light treatments for hair removal due to their expense.
The draft guidance outlines criteria for when PMOS should be suspected, how to assess potential cases, and how to confirm diagnosis. Importantly, it stresses that PMOS should not be ruled out in postmenopausal women. The condition is believed to be more prevalent among women of Black, Asian, and mixed ethnic backgrounds, and healthcare providers are encouraged to take ethnicity into account when evaluating symptoms. Recognizing the significant impact on mental well-being, the guidelines also address the common occurrence of anxiety and depression in those affected by PMOS. Women planning to conceive are advised to seek comprehensive guidance on factors such as weight management, diet, exercise, sleep, and mental health.
Marie Anne Ledingham, consultant clinical advisor for women’s and reproductive health at NICE, described the recommendation for a straightforward annual review as a crucial advancement. She stated, “This new guideline will help improve consistency of care, increase awareness of the condition, and support earlier diagnosis and management.” The draft guidance is open to consultation from 1 July to 11 August 2026, with feedback invited from healthcare workers, patients, and the general public. NICE aims to finalize and publish the updated guidelines on PMOS in December 2026
Read the full article from The BBC here: Read More
Auto Amazon Links: No products found.